Clinical Scorecard: The Evolving Clinical Role of FISH
At a Glance
| Category | Detail |
|---|---|
| Condition | Use of fluorescence in situ hybridization (FISH) in diagnostic cytogenetics, constitutional genetics, and hemato-oncology. |
| Key Mechanisms | Fluorescence-labelled DNA probes hybridize to targeted chromosomal regions, enabling detection of copy-number changes, rearrangements, fusions, amplifications, and deletions in metaphase chromosomes or interphase nuclei. |
| Target Population | People undergoing constitutional genetic evaluation or assessment for hematological malignancies, including suspected acute promyelocytic leukemia. |
| Care Setting | Diagnostic cytogenetics and integrated diagnostic work-ups involving constitutional genetics or hematological malignancies. |
Key Highlights
- FISH provides targeted genomic information without the need for lengthy cell culture and can answer defined clinical questions quickly and reliably.
- FISH is used alongside morphology, flow cytometry, karyotyping, PCR, and sequencing within comprehensive diagnostic work-ups.
- The source describes FISH as particularly valuable when rapid information is required, karyotyping is unsuccessful, or only limited material is available.
- In suspected acute promyelocytic leukemia, FISH can rapidly detect the PML::RARA fusion.
- The source describes FISH as a targeted assay and an orthogonal method for confirming findings, complementing broader genomic approaches.
Guideline-Based Recommendations
Diagnosis
- The article reports that the WHO Classification of Haematolymphoid Tumours calls for integration of morphological, immunophenotypic, molecular, and cytogenetic information for accurate diagnosis.
- The article describes constitutional FISH use to identify microdeletions, aneuploidies, and cryptic subtelomeric translocations, and hematological FISH use to assess recurrent disease-associated abnormalities.
Management
- The article describes FISH as one component of integrated diagnostic work-ups, rather than a replacement for broader genomic approaches.
- The article states that targeted cytogenetic testing contributes to treatment-selection decisions when clinically actionable abnormalities are relevant.
Monitoring & Follow-up
Risks
Patient & Prescribing Data
People evaluated for constitutional genetic abnormalities or hematological malignancies, including suspected acute promyelocytic leukemia.
The article provides no prescribing regimens or patient-level treatment data. It states that FISH can identify abnormalities with diagnostic, prognostic, or therapeutic significance and that targeted cytogenetic testing contributes to treatment selection.
Clinical Best Practices
- The article describes FISH as a method for answering defined clinical questions requiring targeted chromosomal information.
- The article identifies rapid information needs, unsuccessful karyotyping, and limited sample material as contexts in which FISH is particularly valuable.
- The article describes interpretation of FISH alongside morphology, flow cytometry, karyotyping, PCR, sequencing, and other diagnostic information.
- The article describes FISH as a targeted assay and an orthogonal method for confirming findings within integrated diagnostic pathways.
Related Resources & Content
Based on findings from:
A Bright Future for FISH
Faidra Partheniou. The Pathologist, 2026.
https://www.thepathologist.com/issues/2026/articles/november/a-bright-future-for-fish/
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.